A Phase 1 Study of REM-422 in People With Adenoid Cystic Cancer


Full Title

A Phase 1, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma


Researchers want to find the best dose of REM-422 to use in people with advanced adenoid cystic cancer (ACC). ACC most commonly starts in the salivary glands. The people in this study have ACC that has spread and may high levels of a protein called MYB. This protein can cause cancer cells to grow.

REM-422 lowers the amount of the MYB protein. By reducing MYB levels, REM-422 may slow or stop the growth of your cancer. REM-422 is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have ACC that has spread beyond its original location or to other parts of your body.
  • Have completed prior anti-cancer medications at least 3 weeks before getting REM-422 and recovered from any serious side effects.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Alan Ho’s office at 646-541-7062.




Phase I (phase 1)



ClinicalTrials.gov ID